HER 2 POSITIVE BREAST CANCER
Clinical trials for HER 2 POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER 2 POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER 2 POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced breast cancer patients who stopped responding to earlier therapies
Disease control Recruiting nowThis study tests a new drug called A166 in people with HER2-positive breast cancer that has spread and no longer responds to certain previous treatments. About 40 adults aged 18 to 75 will receive A166 to see if it shrinks tumors or slows the disease. The goal is to find a better…
Matched conditions: HER 2 POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New combo therapy aims to boost breast cancer treatment before surgery
Disease control Recruiting nowThis study tests whether adding hormone therapy to standard chemotherapy and HER2-targeted therapy improves tumor response before surgery in people with HER2-positive breast cancer. About 30 adults with stage II to III disease will participate. The goal is to see if this combinat…
Matched conditions: HER 2 POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Legacy Health System • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could routine brain scans catch hidden cancer spread?
Diagnosis Recruiting nowThis trial explores whether it is practical to offer routine brain MRI scans to people with HER2-positive metastatic breast cancer. Participants receive a baseline scan and are then randomly assigned to either two more scans over a year or no further scans. The goal is to see if …
Matched conditions: HER 2 POSITIVE BREAST CANCER
Phase: NA • Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust • Aim: Diagnosis
Last updated Aug 07, 2026 00:00 UTC
-
Biosimilar for breast cancer tracked in real-world study
Knowledge-focused Recruiting nowThis observational study is following 1,000 people with HER2-positive breast cancer who are receiving a pertuzumab biosimilar as part of their routine care. The goal is to see how doctors are using the drug and how well it works in both neoadjuvant (before surgery) and first-line…
Matched conditions: HER 2 POSITIVE BREAST CANCER
Sponsor: Société Algérienne de Formation et Recherche en Oncologie • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC